- Home
- BGLC vs UZX Comparison
BGLC vs UZX Comparison
Compare BGLC & UZX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BGLC | UZX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Malaysia | Japan |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.4M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BGLC | UZX |
|---|---|---|
| Price | $2.18 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.3K | ★ 171.0K |
| Earning Date | 04-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,424,911.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $0.38 |
| 52 Week High | $15.19 | $0.46 |
Technical Indicators
Market Signals| Indicator | BGLC | UZX |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | N/A |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.29 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 66.87 | 0.00 |
Price Performance
Historical ComparisonAbout BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.